Researchers at Ludwig-Maximilians-Universität München have developed a new human cell model that realistically replicates the disease processes behind neurodegenerative dementias such as Alzheimer’s and frontotemporal dementia, offering potential pathways for future therapies.
The breakthrough, led by Professor Dominik Paquet from the LMU Institute for Stroke and Dementia Research, addresses a long-standing gap in dementia research. Previous models, including animal studies and stem cell-derived neurons, have failed to accurately reproduce the adult forms of the tau protein that accumulate in the brains of patients with tauopathies.
“Earlier models mainly produced early, juvenile forms of tau typically seen in developing brains,” the research team explained. “But the disease-relevant variants that appear in adult nerve cells were missing — until now.”
Using CRISPR/Cas9 gene-editing technology, first author Dr. Angelika Dannert modified human nerve cells to express both the adult form of tau and disease-associated mutations. This allows the model to mimic the pathological processes seen in patients more faithfully than previous systems.
The researchers noted that the lack of accurate models has hindered efforts to understand disease mechanisms and develop effective treatments. Neurodegenerative dementias remain incurable and represent a growing challenge for aging societies worldwide.
This new cell model provides a valuable tool for studying how tau abnormalities contribute to neuron damage and could accelerate the screening of potential drug candidates. While still in the research phase, the development marks a significant step toward translating laboratory findings into clinical applications.
The findings were announced on April 23, 2026, by LMU Press and Communication, highlighting the university’s ongoing contributions to neuroscience and translational medicine.
